PFA is still quite safe overall. However, new data out of EHRA 2026 suggest cardiologists have much to learn about minimizing risk during treatment. 

The once-daily pill received FDA approval on April 1. However, the agency has requested additional data on multiple potential side effects. 

The deal includes an upfront payment of $20 million. Stereotaxis could pay up to an additional $25 million if certain regulatory and commercial milestones are met.

The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.

According to Heartflow, Cleerly's actions represent “one of the most egregious examples of piracy in the medical technology industry.” Cleerly commented on the lawsuit, defending the value and integrity of its products. 

SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, made a major impact on the group—and cardiology as a whole—over the last 12 months. 

Early data linked the device with short crossing times, reduced fluoro exposure and no device-related adverse events.

When patients without diabetes land in the hospital after a heart attack or stroke, early treatment with tirzepatide may prove beneficial. 

The OmniaSecure defibrillation lead from Medtronic is already approved for placement in the right ventricle. This latest approval covers the left bundle branch area, opening the door for conduction system pacing and other advanced techniques.

The COVID-19 pandemic created a major shift in how telehealth services were being utilized. Those services were used much more often for some patient populations than others.

The shift comes after a federal court struck down sweeping changes to the pediatric vaccine schedule that went into effect in 2026. The committee of medical experts, which advises on policy at the Centers for Disease Control and Prevention (CDC), will have to focus on a cost-benefit analysis in its future analyses.

“As I step into the role of president, I look forward to continuing strong advocacy for interventional radiologists and ensuring our members are recognized for the value they provide to the healthcare system and improving patient access to high-quality care."